公开(公告)号：US11156617B2

公开(公告)日：2021-10-26

申请号：US15550286

申请日：2016-02-09

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH

发明人： Ugur Sahin ,  Martin Löwer ,  Arbel D. Tadmor ,  Sebastian Boegel ,  Barbara Schrörs ,  Mathias Vormehr ,  Sebastian Kreiter

IPC分类号： G01N33/68 ,  G01N33/50 ,  A61K39/00

摘要： The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.

公开(公告)号：US11920194B2

公开(公告)日：2024-03-05

申请号：US16619761

申请日：2018-06-01

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainzgemeinnützige GmbH

发明人： Ugur Sahin ,  Martin Suchan ,  Barbara Schrörs ,  Martin Löwer ,  Petra Oehm

IPC分类号： C12Q1/68 ,  C12Q1/686 ,  C12Q1/6876

CPC分类号： C12Q1/6876 ,  C12Q1/686 ,  C12Q2600/156

摘要： This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.

公开(公告)号：US20220074948A1

公开(公告)日：2022-03-10

申请号：US17481243

申请日：2021-09-21

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-

发明人： Ugur Sahin ,  Martin Löwer ,  Arbel D. Tadmor ,  Sebastian Boegel ,  Barbara Schrörs ,  Mathias Vormehr ,  Sebastian Kreiter

IPC分类号： G01N33/68 ,  G01N33/50 ,  A61K39/00

摘要： The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.

公开(公告)号：US20190178871A1

公开(公告)日：2019-06-13

申请号：US16301019

申请日：2017-05-10

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRO-Translationable Onkologie an der Unversitatsme dizin der Johannes Gutenberg-Universitat Mainz

发明人： Mathias Vormehr ,  Ugur Sahin ,  Barbara Schrörs ,  Martin Löwer ,  Sebastian Boegel

IPC分类号： G01N33/50 ,  G01N33/53 ,  G01N33/68 ,  A61P35/04

摘要： The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.